Encouraging Results from PAS-004 Chronic Toxicity Studies
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is making significant strides in the biotechnology field with the recent completion of chronic toxicity studies for PAS-004, an innovative macrocyclic MEK inhibitor. This compound is being developed to treat neurofibromatosis type 1 (NF1) and various cancer-related conditions. The studies, which included both rats and dogs, represent a major advancement and have produced promising results that support the company's upcoming clinical efforts.
Study Findings Reveal Strong Safety Profile
The extensive studies were conducted over a prolonged period, confirming previous results from 28-day toxicity assessments. By administering PAS-004 daily for six months to rats and extending the duration to nine months for dogs, the research demonstrated a reassuring safety profile in both species. The study with dogs established the no adverse effect level (NOAEL) at 0.5 mg/kg. This noteworthy finding reinforces PAS-004's consistent safety profile and its potential as an effective cancer treatment.
Insights on Long-term Dosing
The studies indicated that long-term dosing of PAS-004 not only aligned with the previously established safety profile but also appeared to correlate with effective engagement of the targeted pathways. Dosages below the NOAEL are anticipated to lead to significant reductions in pERK, a crucial element in tumor growth pathways. The robust data emerging from these studies further emphasizes PAS-004's potential as a leading option among MEK inhibitors available in the market.
Clinical Applications and Future Trials
With primarily the crystal form of PAS-004 being used in human clinical trials, the consistent adverse event profile observed with its amorphous counterpart suggests promising possibilities as the company gears up for patient dosing. The insights gained from these studies are expected to facilitate more refined clinical practices, effectively targeting cancer cells while minimizing side effects, which is a major concern with traditional therapies.
Leadership Insights
Dr. Tiago Reis Marques, the CEO of Pasithea, expressed his optimism about PAS-004's potential, stating that prolonged suppression of the Mitogen Associated Protein Kinase (MAPK) pathway could enhance its efficacy. He also emphasized the company's eagerness to share further data on PAS-004, particularly initial interim results from their Phase 1 clinical trials, which are expected to provide critical insights into its pharmacokinetic (PK) and pharmacodynamic (PD) profiles.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics is a prominent player in the clinical-stage biotechnology sector, dedicated to developing innovative solutions for central nervous system (CNS) disorders and RASopathies. The company's skilled team, made up of experts in neuroscience and drug development, is on an urgent mission to discover new treatments for debilitating neurological conditions. PAS-004 is just one of their ambitious projects, which also includes research on solid tumors and diseases like Amyotrophic Lateral Sclerosis (ALS).
Frequently Asked Questions
What is PAS-004 developed by Pasithea Therapeutics?
PAS-004 is a next-generation macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 (NF1) and other cancers, and it is currently undergoing clinical trials.
What were the findings of the chronic toxicity studies?
The studies revealed a favorable safety profile for PAS-004, consistent with earlier 28-day study results, and established the NOAEL level at 0.5 mg/kg for dogs.
How long were the PAS-004 studies conducted?
The studies were carried out over six months in rats and nine months in dogs, providing comprehensive data on its safety and long-term effects.
What does the NOAEL mean for PAS-004?
NOAEL stands for No Adverse Effect Level; it indicates the highest dose at which no harmful effects were observed, helping to guide safe dosing in future clinical trials.
What are Pasithea's future plans regarding PAS-004?
Pasithea intends to share more information about PAS-004, including initial results from its first-in-human Phase 1 clinical study, which are expected within the next quarter.
